Categories
Notable Grants

Research Insights

Mass vaccination-ready, reassortment-impaired live virus vaccines against Highly Pathogenic Avian Influenza 

Driven by the urgent need to safeguard the US poultry industry from the devastating impact of Highly Pathogenic Avian Influenza (HPAI), this project leverages a powerful synergy between the University of Georgia’s cutting-edge research capabilities and the established industrial expertise of CEVA Animal Health and BioStone Animal Health to deliver a transformative solution: the first US-approved, mass-vaccination-ready modified live virus (MLV) vaccine against HPAI, accompanied by a comprehensive suite of companion DIVA diagnostics. This involves generating an H5N2 MLV candidate that is stable, grows to high titers (≥10^6 TCID50/mL), and elicits protective immune responses against aggressive H5N1 HPAI challenge after a single dose. The H5N2 MLV will be designed with a chimeric segment and incorporate specific molecular markers with unique sequences. Molecular diagnostic tools, including real-time RT-qPCR and NA-based serological assays, will also be developed to differentiate infected from vaccinated animals (DIVA). Key deliverables include a US-approved, mass-vaccination-ready influenza MLV against HPAI, along with reports, peer-reviewed publications, and other documentation necessary for vaccine and diagnostic tool approvals. The expected outcome is a reduction in the impact of HPAI virus pathogenesis and transmission in commercial poultry premises, specifically layer and turkey operations. The successful vaccine will stimulate humoral, mucosal, and cellular immunity, offering more effective protection against diverse HPAI strains. This project will positively impact the broader US poultry industry by providing a valuable tool for controlling and preventing HPAI outbreaks. Sub-awardees, including CEVA Animal Health and BioStone Animal Health, play crucial roles. CEVA will contribute their expertise in generating the first licensed MLV against avian influenza for poultry use in the US. CEVA and BioStone will also develop nucleic acid-based and ELISA-based diagnostic assays, respectively, providing an all-in-one vaccine and differential diagnostics platform.

Funder: USDA APHIS 

Amount: $1,999,873 

PI: Daniel Perez, College of Veterinary Medicine